FDA approved a new antibiotic to treat community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI).
A new study linking attention-deficit hyperactivity disorder (ADHD) drugs and Parkinson’s disease could cause prescribers to re-think prescribing the medications.
In the past week, the migraine prevention drug market has suddenly heated up, with 2 new approvals by FDA.
Here are the top 3 new approvals from FDA.
While Teva Pharmaceutical’s new migraine prevention drug is unique, it faces competition from another major migraine treatment.
Pharmacy and healthcare experts cautiously praised the planned development of a fast-acting, better version of naloxone (Narcan), which is used to reverse the effects of opioid overdoses.
FDA okayed a first-of-its-kind treatment for hairy cell leukemia (HCL).
Reminiscent of former Turing Pharmaceuticals CEO Martin Shrekli, a different pharma executive defended his company’s 400% price hike on an antibiotic.
FDA recently approved 2 new treatments, heightening competition in the HIV-1 drug marketplace.
FDA cleared the first and only easy-to-swallow liquid drug to treat amyotrophic lateral sclerosis (ALS).